Free Trial

CureVac Q4 2023 Earnings Report

CureVac logo
$4.10 -0.08 (-1.91%)
As of 01/17/2025 04:00 PM Eastern

CureVac EPS Results

Actual EPS
-$0.42
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CureVac Revenue Results

Actual Revenue
$24.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CureVac Announcement Details

Quarter
Q4 2023
Time
N/A

CureVac Earnings Headlines

Why CureVac (CVAC) Shares Are Volatile
2025: Crypto Opportunities You Can’t Afford to Miss
Cryptocurrencies are once again gaining incredible momentum, and savvy investors are positioning themselves to capitalize on this surge in 2025. The question is—will you be among them? With groundbreaking advancements and increasing institutional adoption on the horizon, there's never been a better time to explore the potential gains in crypto. What’s Fueling the Crypto Comeback?
Why CureVac (CVAC) Stock Is Moving
Moderna stock gains on rising flu cases
See More CureVac Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email.

About CureVac

CureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

View CureVac Profile

More Earnings Resources from MarketBeat